106614-28-2

Basic information

• Product Name: METHYL 2,4-DIFLUOROBENZOATE
• Synonyms: RARECHEM AL BF 0213;METHYL 2,4-DIFLUOROBENZOATE;2,4-DIFLUORO-BENZOIC ACID METHYL ESTER;Methyl 2,4-difluorobenzoate ,97%;Methyl 2,4-difluorobenzoate 97%
• CAS NO: 106614-28-2
• Molecular Formula: C₈H₆F₂O₂
• Molecular Weight: 172.13
• EINECS: 1592732-453-0
• Product Categories: Aromatic Esters;Acids & Esters;Fluorine Compounds;C8 to C9;Carbonyl Compounds;Esters
• Mol File: 106614-28-2.mol

Chemical Properties

• Boiling Point: 128-129 °C(lit.)
• Flash Point: 180 °F
• Appearance: /
• Density: 1.384 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.354mmHg at 25°C
• Refractive Index: n20/D 1.4840(lit.)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: METHYL 2,4-DIFLUOROBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2,4-DIFLUOROBENZOATE(106614-28-2)
• EPA Substance Registry System: METHYL 2,4-DIFLUOROBENZOATE(106614-28-2)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 22-37/38-41
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 106614-28-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 2,4-DIFLUOROBENZOATE is used as a reagent for the synthesis of pharmaceuticals, specifically in the development of integrin αvβ3 antagonists. These antagonists are known for their antiplatelet activity, which can be beneficial in the treatment and prevention of blood clot-related conditions.
Used in the Design and Synthesis of Integrin Antagonists:
METHYL 2,4-DIFLUOROBENZOATE plays a significant role in the design and synthesis of integrin αvβ3 antagonists. These compounds have the potential to inhibit the aggregation of platelets, which can be crucial in managing and treating various cardiovascular diseases and conditions related to blood clotting.

InChI:InChI=1/C8H6F2O2/c1-12-8(11)6-3-2-5(9)4-7(6)10/h2-4H,1H3

Upstream product

• 1583-58-0 2,4-difluoro-benzoic acid 
• 367-27-1 2,4-difluorophenol 
• 67-56-1 methanol 
• 15226-74-1 dicobalt octacarbonyl 
• 264135-49-1 2,4-difluorophenyl trifluoromethanesulfonate 
• 13656-36-5 3,5-dichloro-2,4,6-trifluorobenzoic acid 
• 729559-69-7 N-(4-cyanophenyl)-2,4-difluorobenzamide 
• 72482-64-5 2,4-difluorobenzoyl chloride 
• 124-38-9 carbon dioxide 
• 2265-93-2 2,4-difluoro-1-iodobenzene 
• 74-88-4 methyl iodide 

Downstream Products

• 129793-82-4 1-(2,4-Difluorophenyl)-2-(pyridin-3-yl)ethanone 
• 56456-47-4 2,4-difluorobenzyl alcohol 
• 1012867-16-1 2-Fluoro-4-dimethylamino-benzoic acid methyl ester 
• 553672-28-9 methyl 2-fluoro-4-(4-thiomorpholinyl)benzoate 
• 125568-71-0 methyl 2,4-difluoro-5-nitrobenzoate 
• 128272-26-4 [13C₂, D₇]2-(2-fluoro-4-methoxyphenyl)propan-2-ol 
• 204707-42-6 methyl 4-fluoro-2-methoxybenzoate 
• 1235865-75-4 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-fluorobenzoic acid methyl ester 
• 118737-62-5 2,4-difluorobenzoic acid hydrazide 
• 1356585-72-2 C₁₀H₈F₂N₂O₃S 
• 1092277-16-1 (s)-5-(2,4-difluorophenyl)-1,3,4-oxadiazole-2-thiol 
• 1356585-61-9 C₁₀H₈F₂N₂OS 
• 51336-94-8 2-chloro-1-(2,4-dichlorophenyl)ethanone 
• 86386-73-4 fluconazole 

Relevant articles and documents

Br?nsted acid-catalyzed chlorination of aromatic carboxylic acids

The chlorination of aromatic carboxylic acids with SOCl2 has been effectively performed by reacting with a Br?nsted acid as the catalyst. Based on this discovery, an efficient catalytic method that is cheaper than traditional catalytic methods was developed. 20 substrates were chlorinated offering excellent yields in a short reaction time. And the SOCl2/Br?nsted acid system has been used in a larger scale preparative reaction. A dual activation mechanism was proposed to prove the irreplaceable system of SOCl2/Br?nsted acid.

Antibacterial and Antiviral Activities of 1,3,4-Oxadiazole Thioether 4H-Chromen-4-one Derivatives

Various 1,3,4-oxadiazole thioether 4H-chromen-4-one derivatives were conceived. The title compounds demonstrated striking inhibitory effects againstXac,Psa, andXoo. EC50data exhibited that A8 (19.7 μg/mL) had better antibacterial activity againstXoothan myricetin, BT, and TC. Simultaneously, the mechanism of action of A8 had been verified by SEM. The results of anti-tobacco mosaic virus indicated that A9 had the bestin vivoantiviral effect compared with ningnanmycin. From the data of MST, it could be seen that A9 (0.003 ± 0.001 μmol/L) exhibited a strong binding capacity, which was far superior to ningnanmycin (2.726 ± 1.301 μmol/L). This study shows that the 1,3,4-oxadiazole thioether 4H-chromen-4-one derivatives may become agricultural drugs with great potential.

Hydrogen Bond Directed Photocatalytic Hydrodefluorination and Methods of Use Thereof

Methods of synthesizing compounds comprising fluorinated aryl groups are disclosed, wherein said methods utilize hydrogen bond directed photocatalytic hydrodefluorination.

PROCESS FOR THE PREPARATION OF VENETOCLAX

The present disclosure provides novel synthetic process for the preparation of venetoclax. The disclosed processes involve the use of novel intermediates. Processes for the preparation of these intermediates are also disclosed as well as methods for the preparation of particularly useful salts thereof.

Room Temperature Carbonylation of (Hetero) Aryl Pentafluorobenzenesulfonates and Triflates using Palladium-Cobalt Bimetallic Catalyst: Dual Role of Cobalt Carbonyl

An efficient method for the carbonylation of (hetero) aryl pentafluorobenzenesulfonates and triflates under exceptionally mild conditions using palladium/dicobalt octacarbonyl [Pd/Co2(CO)8] has been developed. Besides acting as carbon monoxide (CO) source, Co2(CO)8enhances the reaction rate by accelerating the CO insertion through an in situ generated bimetallic palladium cobalt tetracarbonyl [Pd-Co(CO)4] complex. Under the optimized reaction condition, carbonylation of a wide range of activated and deactivated, as well as sterically hindered and heteroaromatic, substrates proceeded efficiently at room temperature. The high chemoselectivity and improved synthesis of biologically relevant Isoguvacine and Lazabemide intermediates highlights its scope as a valuable synthetic method. The generality of this protocol was further extended to other electrophiles (bromides, chlorides and tosylates). (Figure presented.).

TRICYCLIC PIPERIDINE COMPOUNDS

The present invention relates to compounds of the formula (I), wherein R, R1a, R1b, R2, R3, and X are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), to methods for the preparation of such compounds of formula (I), and especially to their use as TPH modulators.

Inhibition of tobacco bacterial wilt with sulfone derivatives containing an 1,3,4-oxadiazole moiety

A series of new sulfone compounds containing the 1,3,4-oxadiazole moiety were designed and synthesized. Their structures were identified by 1H and 13C nuclear magnetic resonance and elemental analyses. Antibacterial bioassays indicated that most compounds exhibited promising in vitro antibacterial bioactivities against tobacco bacterial wilt at 200 μg/mL. The relationship between structure and antibacterial activity was also discussed. Among the title compounds, 5′c, 5′h, 5′i, and 5′j could inhibit mycelia growth of Ralstonia solanacearum in vitro by approximately 50% (EC50) at 39.8, 60.3, 47.9, and 32.1 μg/mL, respectively. Among them, compound 5′j was identified as the most promising candidate due to its stronger effect than that of Kocide 3000 [Cu(OH)2] within the same concentration range. Field trials demonstrated that the control effect of compound 5′j against tobacco bacterial wilt was better than that of the commercial bactericide Saisentong. For the first time, the present work demonstrated that sulfone derivatives containing 1,3,4-oxadiazole can be used to develop potential bactericides for plants.

SUBSTITUTED PYRAZOLO [4,3-C] PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS

Substituted pyrazolo[4,3-c]pyridine derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a dysregulated protein kinase activity, like cancer.

BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS

A compound having formula (I): wherein: R, A, R1 and R2, are as defined in the specification, and pharmaceutical formulas thereof, and methods of use thereof

Carboxylation and esterification of functionalized arylcopper reagents

Functionalized arylcopper reagents have been produced in good yields at 25 °C from activated copper and the corresponding functionalized aryl iodides without the need of traditional organolithium or Grignard precursors. These organocopper compounds will undergo carboxylation with CO2 to form the corresponding copper benzoates. In turn, these salts can be acidified to produce the functionalized aryl acids or treated with appropriate alkyl halides in the presence of a dipolar aprotic solvent to generate the corresponding aryl esters. This methodology permits the formation of functionalized organic acids and esters that could not be generated by the carboxylation of organomagnesium compounds.